MTOR and breast cancer: Aberrations in the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is a common mechanism of ET resistance [4, 5], and inhibition of this pathway has also improved outcomes among patients with progressive ER+ breast cancer.